SAN DIEGO, CA -- (Marketwired) -- 10/31/13 --
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that management will participate in the following investor events in November and December 2013:
- The Barclays MedTech San Diego Bus Tour at NuVasive's headquarters in San Diego, CA, on Monday, November 25, 2013, at 1:30 p.m. PT
- The NASDAQ OMX Investor Program at the Waldorf Hilton in London, England on Tuesday, December 3, 2013, at 9:30 a.m. GMT
- The Leerink Swann Devices & DNA Bus Tour at NuVasive's headquarters on Wednesday, December 11, 2013, at 2:00 p.m. PT
- The Lazard Capital Markets Southern California Medical Technology Bus Tour at NuVasive's headquarters on Monday, December 16, 2013, at 10:30 a.m. PT
- The Stifel MedTech Madness Bus Tour at NuVasive's headquarters on Friday, December 20, 2013, at 9:30 a.m. PT
A live webcast of each of the formal presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, a replay of the presentations will remain available on the website for 30 days.
About NuVasive
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
Email Contact
Media Contact:
Nicole Collins
NuVasive, Inc.
858-909-1907
Email Contact
Source: NuVasive, Inc.